Tyme Technologies Inc (OQ:TYME)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 17 State St Fl 7
NEW YORK NY 10004-1585
Tel: N/A
Website: https://www.tymeinc.com
IR: See website
Key People
Business Overview
Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system. The Company's lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.
Financial Overview
For the six months ended 30 September 2019, Tyme Technologies Inc revenues was not reported. Net loss decreased 32% to $9.3M. Lower net loss reflects Research and development - Balancing val decrease of 34% to $3.3M (expense), Stock-based Compensation in SGA decrease of 41% to $1.8M (expense), Stock-based Compensation in R&D decrease of 13% to $1.3M (expense).
Employees: 15 as of Mar 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $220.06M as of Sep 30, 2019
Annual revenue (TTM): $0.00M as of Sep 30, 2019
EBITDA (TTM): -$27.99M as of Sep 30, 2019
Net annual income (TTM): -$28.56M as of Sep 30, 2019
Free cash flow (TTM): -$18.78M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 121,950,937 as of Jan 7, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization